[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Population Health Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":661},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,40,67,90,117,148,179,201,224,249,281,310,334,359,386,409,438,470,498,523,546,570,589,614,638],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100555136","international-crds-registry-100555136",false,"NCT06508164","International CRDS Registry","International Calcium Release Deficiency Syndrome Registry","CRDS Registry","CRDS Cohort\n\nInclusion Criterion:\n\n\\- Presence of a rare\\* RYR2 variant that is characterized to be loss-of-function based on in vitro testing#\n\nRYR2 Truncating and Large CNV Cohort\n\nInclusion Criterion:\n\n\\- Presence of a rare\\* RYR2 truncating variant and\u002For large copy number variant involving the RYR2 gene.\n\nCarriers of a Non-Functional RYR2 variant\n\nInclusion Criterion:\n\n\\- Presence of a rare\\* RYR2 variant that is characterized to be neither loss- nor gain-of-function based on in vitro testing#\n\n\\*rare defined as gnomAD prevalence \\\u003C 0.1%\n\n#RYR2 in vitro functional testing will be performed in the laboratory of Dr. Wayne Chen (University of Calgary)","ALL",{"count":20,"type":21},500,"ESTIMATED","26 Years","OBSERVATIONAL","Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.",[26],"Calcium Release Deficiency Syndrome","RECRUITING","2026-06-11",{"date":30,"type":31},"2026-06-15","ACTUAL",{"date":33,"type":31},"2024-11-21",{"date":35,"type":21},"2050-12-31",{"name":37,"class":38},"Population Health Research Institute","OTHER",18,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100530585","evaluation-of-a-clinical-diagnostic-test-for-crds-100530585","NCT06188689","Evaluation of A Clinical Diagnostic Test for CRDS","Evaluation of a Clinical Diagnostic Test for Calcium Release Deficiency Syndrome: The DIAGNOSE CRDS Study","DIAGNOSE CRDS","Cohort 1: Calcium Release Deficiency Syndrome (CRDS) Cases\n\nInclusion criteria:\n\n• Presence of an RyR2 variant confirmed to be loss-of-function on in vitro testing\n\nExclusion criteria:\n\n• Unable to provide informed consent\n\nCohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases\n\nInclusion criteria:\n\n* Satisfy a clinical phenotype consistent with the Expert Consensus Statement\n* Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic\u002Fpathogenic CASQ2 variants\n\nExclusion criteria:\n\n* Unable to provide informed consent\n* Use of a QT prolonging medication, aside from flecainide, at the time of the burst pacing maneuvers\n\nCohort 3: Survivors of Unexplained Cardiac Arrest (UCA)\n\nInclusion criteria:\n\n* Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test\n* Undergone genetic testing that includes screening of RyR2\\*\n\nExclusion criteria:\n\n* Unable to provide informed consent\n* Use of a QT prolonging medication at the time of the burst pacing maneuvers\n\n  * Among survivors of UCA that possess a rare RyR2 variant in the absence of a CPVT phenotype, in vitro functional testing will be performed in order to confirm it is not loss- or gain-of-function (and will be arranged through the laboratory of Dr. Wayne Chen at the University of Calgary).\n\nCohort 4: SVT controls\n\nInclusion criteria:\n\n• Undergoing an invasive electrophysiology study\n\nExclusion criteria:\n\n* Ventricular cardiomyopathy\n* Ventricular pre-excitation\n* Long QT syndrome\n* Use of a QT prolonging medication at the time of the EP study\n* Use of a Class I or Class III anti-arrhythmic drug at the time of the EP study\n* Known obstructive coronary artery disease (existing coronary stenosis \\>50%)\n* Unable to provide informed consent",{"count":49,"type":21},400,"INTERVENTIONAL",[52],"NA","Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.",[55],"Calcium Release Deficiency Syndrome (CRDS)",[57],"cardiac arrhythmia, sudden cardiac death, cardiac ryanodine receptor, unexplained cardiac arrest","2026-05-28",{"date":60,"type":31},"2026-06-01",{"date":62,"type":31},"2023-02-02",{"date":64,"type":21},"2028-03",{"name":37,"class":38},19,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":50,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100480091","bariatric-surgery-for-the-reduction-of-cardiovascular-events-randomized-controlled-trial-100480091","NCT05531474","Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial","BRAVE","Inclusion Criteria:\n\n1. Body mass index ≥30 kg\u002Fm2; OR BMI ≥30 kg\u002Fm2 to 34.9 kg\u002Fm2 and have type 2 diabetes or are \\>55 years of age\n2. Age ≥18 years\n3. High-risk CVD, defined as the presence of any one of the following:\n\n   1. High-risk coronary artery disease (CAD) (i.e., history of MI, percutaneous coronary intervention, coronary artery bypass grafting, or stenoses ≥ 50% in 2 or more major coronary arteries)\n   2. Left ventricular ejection fraction (LVEF) \\< 40%\n   3. Heart failure with preserved ejection fraction (LVEF \\> 40%) and either HF hospitalization in the last 2-years or N-terminal pro b-type natriuretic peptide (NT-proBNP) \\> 300 pg\u002Fml or BNP \\> 100 pg\u002Fml in the past 12 months\n   4. Documented atrial fibrillation (AF) with CHA2DS2-VASc ≥2 stroke risk score\n   5. History of any stroke\n   6. Documented peripheral arterial disease (PAD) (i.e., peripheral revascularization of the iliac, infra-inguinal or carotid arteries; limb or foot amputation for arterial vascular disease; or ≥50% carotid or peripheral artery stenosis)\n\nExclusion Criteria:\n\n1. Hospital admission for HF, myocardial infarction, stroke or coronary revascularization within 30 days of randomization\n2. Percutaneous coronary intervention with a drug eluting stent within 90 days of randomization.\n3. Pregnancy\n4. Contraindication to bariatric surgery\n5. Prior bariatric surgery, other than gastric banding\n6. Life expectancy \\<2 years from non-cardiovascular causes\n7. Inability to provide informed consent","18 Years",{"count":76,"type":21},700,[52],"The primary objective of this study is to evaluate if, in patients with severe obesity (body mass index (BMI) ≥30 kg\u002Fm2) and high-risk cardiovascular disease (CVD), bariatric surgery compared to medical weight management (MWM) safely reduces the risk of major cardiovascular events. The cost-effectiveness of bariatric surgery will also be examined. Separate sub-studies will be performed to examine the relationship between bariatric surgery and mental health and cognition (BRAVE-Mind), cardiac structure and function, genomics, proteomics and metabolomics.",[80,81],"Cardiovascular Complication","Bariatric Surgery Candidate","2026-05-25",{"date":58,"type":31},{"date":85,"type":31},"2020-11-02",{"date":87,"type":21},"2027-07-01",{"name":37,"class":38},1,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":50,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100503883","phase-3-short-term-anti-arrhythmic-therapy-for-post-operative-af-in-cardiac-surgery-patients-pilot-trial-100503883","NCT05841056","Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial","Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients (START-POAF) Pilot Trial","START-POAF","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Have undergone cardiac surgery including CABG, valve surgery, ascending aorta replacement, or combinations thereof within 14 days of randomization;\n3. Had new-onset POAF (or flutter), documented by 12-lead ECG or lasting ≥ 1 hour on telemetry. Patients can be in AF or sinus rhythm at the time of randomization;\n4. Expected to receive 3 g - 5 g of amiodarone loading dose post-surgery.\n5. Expected to be ready for hospital discharge within 48 h of randomization.\n\nExclusion Criteria:\n\n1. Documented preoperative history of paroxysmal, persistent or permanent AF;\n2. Planned use of a class I or III anti-arrhythmic drug (other than study drug);\n3. Patients who have undergone heart transplant, complex congenital heart surgery, isolated ventricular assist device insertion, or AF ablation (surgical or catheter);\n4. Known allergy to ECG adhesives;\n5. Contraindication to amiodarone (i.e. hyperthyroidism, severe restrictive or obstructive lung disease, Long QT syndrome, PR \\> 240 ms, high-grade AV block).\n6. Individuals who are pregnant, breastfeeding, or of childbearing potential - female subjects, premenopausal who are not surgically sterile, or, if sexually active not practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, who have a positive pregnancy test at screening",{"count":49,"type":21},[100],"PHASE3","The START-POAF pilot study is a prospective, open-label two-arm, randomized controlled trial with blinded assessment of outcomes (PROBE). This pilot study will assess Atrial Fibrillation (AF) recurrence and burden in patients with new-onset AF following cardiac surgery.",[103],"Atrial Fibrillation New Onset",[105,106,107],"cardiac surgery","heart rhythm monitoring","amiodarone","2026-05-22",{"date":110,"type":31},"2026-05-27",{"date":112,"type":31},"2024-06-13",{"date":114,"type":21},"2028-11-30",{"name":37,"class":38},2,{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":50,"phases":127,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100632273","phase-2-glucagon-like-peptide-1-receptor-agonists-for-endovascular-stroke-thrombectomy-100632273","NCT07511543","Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy","A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy","LEAST","Inclusion Criteria:\n\n1. Age 18 years or above on the date of randomization.\n2. EVT for an LVO in the anterior circulation, defined as the intracranial segment of the internal carotid artery (ICA) and\u002For the M1 or proximal M2 segment of the middle cerebral artery (MCA).\n3. National Institutes of Health Stroke Scale (NIHSS) ≥ 6 points at the time of randomization.\n4. Pre-stroke modified Rankin Scale (mRS) 0 or 1.\n5. Ability to randomize within 6 hours from the end of EVT.\n6. Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR).\n\nExclusion Criteria:\n\n1. Pregnancy or breast-feeding.\n2. Renal insufficiency (creatinine clearance \\\u003C 30mL\u002Fmin).\n3. Cirrhosis or severe hepatic dysfunction, characterized by jaundice, encephalopathy or coagulopathy.\n4. History of pancreatitis in the year prior to randomization or evidence of acute pancreatitis on randomization.\n5. Active sepsis on randomization.\n6. Cancer, regionally advanced or metastatic, or for which treatment had been administered within 6 months from randomization, or hematological cancer that is not in complete remission.\n7. Any terminal medical condition with life expectancy of less than 3 months.\n8. Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).\n9. Body mass index (BMI) less than 19.\n10. Known hypersensitivity to GLP-1 RAs.\n11. Active treatment with an GLP-1RA prior to randomization.\n12. Refusal or inability to administer subcutaneous (SC) injections by the patient or a caregiver.\n13. Close affiliation with the investigational site.",{"count":126,"type":21},100,[128],"PHASE2","Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain. However, even with this treatment, over half of the patients either pass away or are left with serious disabilities within three months. This is partly because, even in cases of a successful EVT, brain tissue damage continues to grow. Extent of brain damage is a major factor in how well a patient recovers. Studies in animals have shown that a drug called semaglutide might help protect the brain and improve recovery after a stroke. Semaglutide is currently used for the treatment of diabetes and obesity and is given as a weekly injection under the skin.\n\nThe investigators are hoping to test whether giving semaglutide to stroke patients undergoing EVT can improve their recovery. A very large study at many hospitals is needed to answer this question. The investigators are starting with a smaller study to gain information on whether it is possible to perform a larger definitive one, and if so, how best to plan for it. In this first step the investigators will study 100 patients with stroke who are scheduled for EVT in approximately 10 stroke centers across Canada. These patients will be randomly divided (like flipping a coin) into two groups: one will receive weekly semaglutide injections for 12 weeks, while the other will not receive the drug. The investigators will track how many patients agree to participate, how many stay in the study, and how well they follow the treatment plan. The investigators will also monitor the patients' recovery, overall health, and any side effects from the treatment. These results will provide important information to plan the larger study with the goal of reducing death rates and long-term disability in stroke patients undergoing EVT.",[131],"Ischemic Stroke",[133,134,135,136,137,138],"semaglutide","stroke","endovascular thrombectomy","large vessel occlusion","glucagon-like peptide-1 receptor agonist","GLP-1 RA","NOT_YET_RECRUITING","2026-04-15",{"date":142,"type":31},"2026-04-20",{"date":144,"type":21},"2026-06-30",{"date":146,"type":21},"2028-06-30",{"name":37,"class":38},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":50,"phases":158,"briefSummary":159,"conditions":160,"keywords":164,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},"100421926","phase-3-low-dose-colchicine-in-patients-with-peripheral-artery-disease-to-address-residual-vascular-risk-100421926","NCT04774159","Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk","Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial","LEADER-PAD","Inclusion criteria:\n\n1. Age \\> 18 years\n2. Symptomatic atherosclerotic LE PAD fulfilling at least one of the following:\n\n   a. Intermittent claudication with ankle\u002Farm blood pressure ratio\\* (ABI ≤ 0.90) or artery stenosis ≥ 50% plus one of i. \\>1 vascular bed affected by atherosclerosis ii. Diabetes iii. Heart failure iv. Chronic kidney disease (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2)\n\n   b. Rest pain (mostly in foot) OR necrosis of limb OR gangrene of limb (corresponding to either Fontaine stages 3 or 4 OR Rutherford Classification categories 4 to 6). All must have an ankle\u002Farm blood pressure ratio\\* (ABI ≤ 0.90) OR artery stenosis ≥ 50%.\n\n   \\* In cases of incompressible ankle arteries, the presence of toe pressure ≤ 60 mm Hg or toe-brachial index ≤ 0.70 is acceptable\n\n   c. Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty\u002Fstent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery\n\n   d. Leg or foot amputation for arterial vascular indications\n3. Written or verbal informed consent from the patient\n\nExclusion Criteria:\n\n1. Contraindication to colchicine\n2. Long term requirement for colchicine for another clinical indication\n3. Active diarrhoea\n4. eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n5. Cirrhosis or severe chronic liver disease\n6. Woman who is pregnant, or breast-feeding or of child-bearing potential not protected by reliable contraception or is planning conception during the study\n7. Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (with the exception of azithromycin)\n8. Patients who are deemed unlikely to return for follow-up\n9. Patients with life expectancy \\\u003C 1 year",{"count":157,"type":21},6150,[100],"The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.",[161,162,163],"Peripheral Arterial Disease","Atherosclerosis of Extremities","Inflammation",[165,166,167,168,169],"Acute limb ischemia","Myocardial Infarction","Stroke","Cardiovascular death","Mortality","2026-03-20",{"date":172,"type":31},"2026-03-24",{"date":174,"type":31},"2021-05-06",{"date":176,"type":21},"2029-12",{"name":37,"class":38},70,{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":18,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":50,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100628961","phase-3-combination-antithrombotic-treatment-for-prevention-of-recurrent-ischemic-stroke-in-intracranial-atherosclerotic-disease-catis--icas-100628961","NCT07468448","Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)","CATIS-ICAS","Inclusion Criteria:\n\n1. Age \\> 40 years\n2. Ischemic stroke or high-risk TIA (motor and\u002F or speech involvement)\n3. Randomization within 30 days of index stroke\n4. Stroke potentially attributable to ICAS 30-99% (or flow gap on time-offlight MRA) of a major intracranial artery (internal carotid artery, middle cerebral artery, anterior cerebral artery, posterior cerebral artery, intracranial vertebral artery, or basilar artery) by MRA or CTA or catheter angiography.\n5. Modified Rankin Scale Score \\\u003C 4 at randomization\n6. Ability to obtain informed consent prior to randomization.\n\nExclusion Criteria:\n\n1. Cardioembolic stroke\n2. Indication for long-term dual antiplatelet or anticoagulant therapy (e.g. venous thromboembolism, coronary stent, mechanical prosthetic valve)\n3. Intracranial arterial stenosis secondary to causes other than atherosclerosis e.g. dissection, moya moya disease\n4. Substantial extracranial carotid artery disease ipsilateral to the qualifying stroke with plans for carotid revascularization\n5. Intended intracranial stenting for the qualifying stroke\n6. Symptomatic hemorrhagic transformation of the index stroke, or neuroradiological class 2 (PH2 type) or symptomatic class 3 on Heidelberg scale prior to randomization\n7. Previous non-traumatic intracerebral hemorrhage, non-aneurysmal subarachnoid hemorrhage (treated aneurysmal subarachnoid hemorrhage will be allowed)\n8. Subdural hematoma within 12 months prior to randomization or traumatic brain hemorrhage within 1 month prior to randomization\n9. Advanced kidney disease at randomization (eGFR \\\u003C15 ml per minute)\n10. Platelet count less than 100,000\u002Fmm3 at enrolment or other bleeding diatheses\n11. Uncontrolled hypertension with BP consistently above 180 mmHg for systolic and 110mmHg for diastolic while on treatment\n12. Known hypersensitivity or contraindication to ASA, clopidogrel or rivaroxaban\n13. Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) or P- glycoprotein (P-gp)\n14. Females of childbearing potential who are not surgically sterile, pregnant, or breast-feeding\n15. Previous randomization to this study\n16. Participating in a study with an investigational drug or medical device that would interfere with the study at the time of randomization (participants that are no longer in an active arm of a study but are being followed may be randomized)\n17. Terminal medical illness with life expectancy less than 1 year","40 Years",{"count":188,"type":21},1172,[100],"CATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for 90 days followed by placebo plus aspirin daily for preventing recurrent stroke in those with ischemic stroke secondary to intracranial atherosclerotic disease (ICAD) of 30-99%, when started within 30 days of index stroke.",[131,192],"Intracranial Atherosclerosis","2026-03-09",{"date":195,"type":31},"2026-03-12",{"date":197,"type":21},"2026-05-30",{"date":199,"type":21},"2029-12-30",{"name":37,"class":38},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":50,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100561251","phase-3-colchicine-for-the-reduction-of-dependency-and-vascular-events-after-an-acute-intracerebral-hemorrhage-100561251","NCT06587737","Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage","A Double-blind, Randomized, Placebo-controlled, Phase III Study for Reducing Dependency and Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous Intracerebral Hemorrhage and Established, or Risk Factors for, Atherosclerosis","CoVasc-ICH2","Inclusion Criteria:\n\nAdult patients presenting with spontaneous intraparenchymal hemorrhage within 72 hours of symptom onset and qualifying for at least one of the following categories:\n\ni. history of symptomatic coronary, peripheral and\u002For carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical\u002Fintracranial atherosclerotic disease causing any degree of stenosis\u002Focclusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL\u002Fmin), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease).\n\nExclusion Criteria:\n\n* secondary causes of ICH (such as trauma, macrovascular anomalies, neoplasms or bleeding diathesis)\n* ICH volume more than 60ml in the last imaging scan prior to consent\n* Glasgow Coma Scale (GCS) score less than 7 or being intubated at the time of consent\n* inflammatory bowel disease or chronic diarrhea\n* cirrhosis or severe hepatic dysfunction\n* renal insufficiency (eGFR\\\u003C15mL\u002Fmin)\n* concurrent or planned treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir\u002Fritonavir, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir\u002Fritonavir) or P-gp inhibitors (cyclosporine, ranolazine)\n* pregnancy or breast-feeding\n* known allergy or sensitivity to colchicine\n* a strong indication for colchicine where assignment to placebo is deemed unacceptable\n* estimated life expectancy less than 6 months at the time of enrollment, and\n* inability to adhere to study procedures",{"count":210,"type":21},1125,[100],"Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant periods after hemorrhage. These findings highlight the need for novel treatments that modify the high risk for major vascular events and functional outcomes in ICH survivors.\n\nThe objective of CoVasc-ICH 2 is to demonstrate that oral colchicine 0.5 mg daily is superior to placebo for improving the outcomes of ICH survivors with evidence or risk factors for atherosclerosis, when started within 72 hours from ICH onset.",[214,215,167,216],"Colchicine","ICH - Intracerebral Hemorrhage","Dependence","2026-02-23",{"date":219,"type":31},"2026-02-25",{"date":197,"type":21},{"date":222,"type":21},"2028-10-30",{"name":37,"class":38},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":50,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":89},"100621208","head-of-bed-after-ischemic-stroke-thrombectomy-hobit-100621208","NCT07367633","Head of Bed After Ischemic Stroke Thrombectomy (HoBIT)","A Pragmatic, Multicentre, Adaptive, Prospective, Open-label, Blinded Endpoint Randomized Clinical Trial Assessing the Impact of Head-of-bed Positioning at 0-degrees Versus 30-degrees or More on Functional Recovery Following Endovascular Thrombectomy for Anterior Circulation Large Vessel Occlusion Stroke.","HoBIT","Inclusion Criteria:\n\n* Age 18 years or older on the date of randomization\n* Endovascular thrombectomy (EVT) for large vessel occlusion (LVO) in the anterior circulation, according to current guidelines and local standards of clinical care. The definition of LVO may include the intracranial segment of the internal carotid artery (ICA), and\u002F or the M1 segment (proximal, mid, distal) of the middle cerebral artery (M1-MCA), and\u002F or the proximal M2 segment of the MCA (M2-MCA)\n* Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR), or via a deferred consent process approved by the relevant ethics committee, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n* Mechanical ventilatory support for acute medical condition prior to procedure (i.e. required for reasons other than procedure)\n* Symptomatic congestive heart failure, chronic obstructive pulmonary disease, or any other medical condition that would make either HoB position inappropriate for patient care in the judgement of the investigator.\n* Any condition, such as but not limited to, agitation\u002F delirium or severe nausea\u002F vomiting, that, in the view of the investigator, is expected to significantly impede maintaining the assigned HoB\n* Any condition with life expectancy of less than 3 months\n* Inability to randomize within 1 hour from the end of the EVT",{"count":233,"type":21},2240,[52],"Endovascular thrombectomy (EVT), also known as clot retrieval, is a procedure that improves recovery for people who suffer a stroke by removing blood clots from large blood vessels in the brain. However, half of the patients undergoing EVT to remove the clot from a brain vessel still face lasting disabilities or even die within three months.\n\nThe investigators of the HoBIT trial are trying to find out if the position of the head of bed improves recovery in patients who undergo EVT after suffering from a stroke.\n\nThe purpose of this study is to establish the benefit of head of bed positioning at 0-degrees compared with 30-degrees or more after EVT for improving functional outcomes in adults that suffer from a stroke.",[237,167,131],"Large Vessel Occlusion",[239,134,136,135,240],"head of bed","EVT","2026-02-03",{"date":243,"type":31},"2026-02-05",{"date":245,"type":21},"2026-03",{"date":247,"type":21},"2028-12",{"name":37,"class":38},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":257,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":50,"phases":260,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":279,"locationsCount":280},"100360075","phase-4-anticoagulation-for-stroke-prevention-in-patients-with-recent-episodes-of-atrial-fibrillation-occurring-transiently-with-stress-100360075","NCT03968393","Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress - The ASPIRE-AF Trial","ASPIRE-AF","Inclusion Criteria:\n\n1. have ≥1 episode of clinically important AFOTS during any of the following conditions:\n\n   1. noncardiac surgery in the past 35 days, with at least an overnight hospital admission aftersurgery;\n   2. noncardiac day surgery resulting in a large enough physiological insult to be able to cause AFOTS, as judged by the local investigator; or\n   3. acute medical illness requiring hospital admission in the past 35 days and resulting in a large enough physiological insult to be able to cause AFOTS, as judged by the local investigator;\n2. sinus rhythm at the time of randomization;\n3. any of the following high-risk criteria:\n\n   1. age 55-64 years, and having either known cardiovascular disease, recent major vascular surgery, a CHA2DS2VASc score ≥3, or an elevated postoperative troponin level;\n   2. age 65-74 years, and having either known cardiovascular disease, recent major vascular surgery, a CHA2DS2VASc score ≥2, or an elevated postoperative troponin level; OR\n   3. age ≥75 years.;\n4. provide written informed consent\n\nExclusion Criteria:\n\n1. any cardiac diagnosis as the primary reason for hospital admission;\n2. history of documented chronic AF prior to noncardiac surgery;\n3. need for long-term systemic anticoagulation;\n4. ongoing need for long-term dual antiplatelet treatment;\n5. contraindication to oral anticoagulation;\n6. severe renal insufficiency (CrCl \\\u003C20 ml\u002Fmin);\n7. severe liver cirrhosis (i.e., Child-Pugh Class C)\n8. acute stroke in the past 14 days;\n9. underwent cardiac surgery in the past 35 days;\n10. history of nontraumatic intracranial, intraocular, or spinal bleeding;\n11. hemorrhagic disorder or bleeding diathesis;\n12. expected to be non-compliant with follow-up and\u002For study medications;\n13. known life expectancy less than 1 year due to concomitant disease;\n14. women who are pregnant, breastfeeding, or of childbearing potential who are not taking effective contraception; OR\n15. previously enrolled in the trial","55 Years",{"count":259,"type":21},2270,[261],"PHASE4","Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.",[167,264],"Atrial Fibrillation",[266,267,268,269,270,271,272],"Transient Atrial Fibrillation","Perioperative Atrial Fibrillation","Non-vitamin K Oral Anticoagulation","Noncardiac Surgery","PROBE Design","Medical Illness","Stress","2026-01-08",{"date":275,"type":31},"2026-01-12",{"date":277,"type":31},"2019-06-14",{"date":247,"type":21},{"name":37,"class":38},105,{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":50,"phases":290,"briefSummary":291,"conditions":292,"keywords":295,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":309},"100334586","phase-3-low-inr-to-minimize-bleeding-with-mechanical-valves-trial-100334586","NCT03636295","Low INR to Minimize Bleeding With Mechanical Valves Trial","LIMIT","Inclusion criteria:\n\n* Age is 18 or older at the time of enrolment\n* Have had a bileaflet mechanical heart valve implant in the aortic position 3 or more months ago\n* Written informed consent from either the patient or substitute decision maker\n\nExclusion criteria:\n\n* Has a second implanted mechanical valve (any position)\n* Lower boundary of planned INR range is less than 2.0\n* Pregnant or expecting to become pregnant during the study follow-up",{"count":289,"type":21},2625,[100],"This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.",[293,294],"Bleeding Post-mechanical Valve Replacement","Thromboembolism Post-mechanical Valve Replacement",[296,297,298,299,300],"Mechanical valve replacement","Vitamin K antagonist","INR targets","Bleeding","Thromboembolism","2025-12-31",{"date":303,"type":31},"2026-01-06",{"date":305,"type":31},"2019-09-05",{"date":307,"type":21},"2026-12-31",{"name":37,"class":38},35,{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":18,"minAge":318,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":50,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":178},"100419595","hip-fracture-accelerated-surgical-treatment-and-care-track-2-trial-100419595","NCT04743765","HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial","HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 (HIP ATTACK-2) Trial","HIP ATTACK-2","Inclusion Criteria:\n\n1. age ≥45 years;\n2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;\n3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and\n4. informed consent.\n\nExclusion Criteria:\n\n1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;\n2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);\n3. patients with peri-prosthetic fracture, open fracture or bilateral fractures;\n4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma);\n5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;\n6. patients refusing consent; or\n7. patients previously enrolled in HIP ATTACK-2.","45 Years",{"count":320,"type":21},1100,[52],"The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.",[324,325],"Hip Fractures","Myocardial Injury","2025-09-25",{"date":328,"type":31},"2025-10-01",{"date":330,"type":31},"2021-11-22",{"date":332,"type":21},"2027-05-31",{"name":37,"class":38},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":50,"phases":343,"briefSummary":344,"conditions":345,"keywords":348,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":66},"100384372","phase-3-the-direct-oral-anticoagulation-versus-vitamin-k-antagonist-after-cardiac-surgery-trial-100384372","NCT04284839","The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","DANCE","Inclusion Criteria:\n\n1. Age ≥18 years at the time of enrolment,\n2. Open heart surgery in the last 10 days,\n3. Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),\n4. Informed consent from either the patient or a substitute decision-maker.\n\nExclusion Criteria:\n\n1. Mechanical valve replacement,\n2. Antiphospholipid syndrome (triple positive),\n3. Severe renal failure (Cockcroft-Gault equation; creatinine clearance \\\u003C15 ml\u002Fmin),\n4. Known significant liver disease (Child-Pugh classification B and C),\n5. Left ventricular thrombus,\n6. Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,\n7. Known contraindication for any DOAC or VKA,\n8. Women who are pregnant, breastfeeding, or of childbearing potential,\n9. Surgery including left ventricular assist device implantation or cardiac transplantation,\n10. Previously enrolled in this trial,\n11. Follow-up not possible,\n12. History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.",{"count":342,"type":21},3500,[100],"The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.",[346,347],"Bleeding Post Cardiac Surgery","Indication for Anticoagulation",[349,350,299],"Direct Oral Anticoagulant","Vitamin K Antagonist","2025-09-23",{"date":353,"type":31},"2025-09-29",{"date":355,"type":31},"2021-07-18",{"date":357,"type":21},"2027-06",{"name":37,"class":38},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":50,"phases":369,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":385},"100483871","phase-3-reducing-mortality-in-adults-with-advanced-hiv-disease-revive-100483871","NCT05580666","Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)","Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial","REVIVE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Documented HIV infection\n3. CD4 count criteria:\n\n   i. CD4 count ≤ 100 cells\u002Fmm3 within past 4 weeks; or\n\n   ii. Documented CD4 nadir ≤ 100 cells\u002Fmm3 and complete interruption of ART for ≥ 6 months; or\n\n   iii. Documented CD4 count ≤ 100 cells\u002Fmm3 if ART-naive\n4. Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment\n\nExclusion Criteria:\n\n1. Contraindications to azithromycin:\n\n   i. Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or\n\n   ii. Personal or family history of QT-prolongation\n2. Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators)\n3. Off-label azithromycin prophylaxis or requirement for prolonged (\\> 7 days) azithromycin (or macrolide) therapy",{"count":368,"type":21},8000,[100],"A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.",[372],"HIV Disease Progression",[374,375,376,169],"Human immunodeficiency virus","Antiretroviral therapy","Azithromycin","2025-08-26",{"date":379,"type":31},"2025-09-03",{"date":381,"type":31},"2023-05-08",{"date":383,"type":21},"2029-05-31",{"name":37,"class":38},52,{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":50,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":89},"100366309","higher-vs-lower-dose-heparin-for-pci-100366309","NCT04049591","Higher vs. Lower Dose Heparin for PCI","A Randomized Trial of Higher vs. Lower Dose Heparin for PCI","HD-PCI","Inclusion Criteria:\n\n\\- Patients undergoing elective PCI\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Planned chronic total occlusion PCI\n* Non-resident precluding follow up through local registries\n\nHospital (Cluster) Eligibility Criteria\n\nHospitals will be eligible to participate if they meet the following criteria:\n\n* Submit PCI procedure data to a compatible registry that is able to provide data for the trial\n* Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period",{"count":395,"type":21},16000,[52],"HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).",[399,400],"Cardiovascular Diseases","Percutaneous Coronary Intervention","2025-07-28",{"date":403,"type":31},"2025-07-31",{"date":405,"type":31},"2022-03-02",{"date":407,"type":21},"2025-12",{"name":37,"class":38},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":50,"phases":419,"briefSummary":420,"conditions":421,"keywords":424,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":437},"100553480","pericardiotomy-in-cardiac-surgery-100553480","NCT06486636","Pericardiotomy in Cardiac Surgery","Pericardiotomy in Cardiac Surgery Trial","PRINCE","Inclusion Criteria:\n\n* Patients greater than or equal to 18 years of age\n* Requiring surgical intervention on the proximal aorta, cardiac valves, and\u002For coronary arteries\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of atrial fibrillation or flutter\n* Cardiac surgery procedures not included in the inclusion criteria (planned ventricular assistance device, aortic arch, transplantation surgery)\n* Prior cardiac surgery requiring opening of the pericardium\n* Previous surgical instrumentation of the left pleural cavity\n* Patient undergoing minimally invasive cardiac surgery",{"count":418,"type":21},1400,[52],"PRINCE is an international, multicentre, randomized controlled trial of posterior pericardiotomy in patients without a history of atrial fibrillation (AF) or flutter undergoing cardiac surgery.",[264,422,423],"Atrial Flutter","Cardiac Events",[425,426,427,428],"Pericardiotomy","Cardiac Surgery","Hospital Readmission","Post-Operative Atrial Fibrillation","2025-07-09",{"date":431,"type":31},"2025-07-14",{"date":433,"type":31},"2024-10-21",{"date":435,"type":21},"2031-09-01",{"name":37,"class":38},4,{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":50,"phases":448,"briefSummary":449,"conditions":450,"keywords":453,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":469},"100493146","physiology-guided-vs-angiography-guided-non-culprit-lesion-complete-revascularization-for-acute-mi--multivessel-disease-100493146","NCT05701358","Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease","A Randomized Trial of Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization Strategies & an Observational Study of Optical Coherence Tomography in Patients With Acute MI & Multivessel Coronary Artery Disease","COMPLETE-2","Inclusion Criteria:\n\n1. Patients presenting with STEMI or type 1 NSTEMI and within 72 hours of successful culprit-lesion PCI\n2. Residual coronary artery disease defined as at least 1 additional non-infarct-related coronary artery stenosis that meets all of the following criteria:\n\n   1. Amenable to successful treatment with PCI\n   2. At least 50% diameter stenosis by visual estimation\n   3. At least 2.5 mm in diameter\n3. Planned complete revascularization strategy for qualifying MI\n\nExclusion Criteria:\n\n1. Planned or prior coronary artery bypass graft (CABG) surgery\n2. Inability to clearly identify a culprit lesion for STEMI or NSTEMI based on angiographic appearance and\u002For ECG changes and\u002For regional wall motion abnormalities\n3. Prior PCI of a non-culprit lesion in a different vessel from the culprit lesion within 45 days of randomization\n4. Planned medical treatment of all qualifying non-culprit lesions (i.e., no PCI)\n5. Presence of severe non-culprit-lesion stenosis with reduced epicardial flow (TIMI flow ≤ 2) or \\>90% visual diameter stenosis\n6. Presence of a chronic total occlusion (CTO) if it is the only qualifying non-culprit lesion (patients with a CTO plus additional qualifying non-culprit lesions are eligible)\n7. The only qualifying non-culprit lesion is in the same vessel territory as the culprit lesion\n8. Baseline STEMI or NSTEMI was due to a suspected non-atherothrombotic mechanism such as type 2 MI (supply-demand mismatch), including spontaneous coronary artery dissection or coronary artery embolism\n9. Non-cardiovascular co-morbidity with expected life expectancy \\\u003C2 years\n10. Any other medical, geographic, or social factor making study participation impractical or precluding 5 year follow-up",{"count":447,"type":21},5100,[52],"COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI).\n\nCOMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.",[451,452],"Acute Myocardial Infarction","Coronary Artery Disease",[454,455,456,457,458,459,460],"NSTEMI","STEMI","multi-vessel disease","optical coherence tomography","FFR","RFR","percutaneous coronary intervention","2025-06-16",{"date":463,"type":31},"2025-06-19",{"date":465,"type":31},"2023-06-22",{"date":467,"type":21},"2028-06",{"name":37,"class":38},113,{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":50,"phases":479,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":4},"100593796","early-phase-1-doac-or-vka-in-patients-with-af-and-stroke-while-on-doac---a-pilot-trial-100593796","NCT07011095","DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","A Pilot Trial to Assess the Feasibility of a Multicentre, Phase IV, Prospective, Randomized, Open-label, Two-arm Study With Blinded-endpoint Evaluation to Investigate Vitamin K Antagonist (VKA) Therapy Compared With Direct Oral Anticoagulant (DOAC) Therapy in Male and Female Participants With Atrial Fibrillation and Recent Ischemic Stroke While on a DOAC","SWITCH-AF","Inclusion Criteria:\n\n1. Written informed consent provided.\n2. Age \\>18 years.\n3. Documented history of AF or atrial flutter.\n4. Ischemic stroke while on a DOAC within 14 days prior to enrollment identified on imaging.\n5. In the opinion of the investigator, it is safe to initiate oral anticoagulation with either a VKA or a DOAC within 24 hours of randomization-\n\nExclusion Criteria:\n\n1. There is strong evidence for the qualifying stroke event to be associated with permanent discontinuation of DOAC therapy (for any reason)\n2. Patient is unable or unwilling to take oral anticoagulation\n3. History of intracranial bleeding.\n4. Patient is on chronic hemodialysis or likely to need renal replacement therapy during the course of the trial.",{"count":126,"type":21},[480],"EARLY_PHASE1","People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people. Options include continuing the same DOAC, switching to another DOAC or switching to warfarin.\n\nThe investigators of the SWITCH-AF trial are trying to find out whether switching to warfarin or continuing a DOAC is better for preventing stroke.\n\nThe purpose of this study, called a pilot study, is to test the study plan and to find out whether enough participants will join a larger study that answers the question. A pilot study involves a small number of participants and it is not expected to tell us which treatment is better.",[483,484],"Atrial Fibrillation (AF)","Stroke (in Patients With Atrial Fibrillation)",[134,486,487,476,488,489,490],"atrial fibrillation","A-Fib","DOAC","Warfarin","Anticoagulant","2025-06-04",{"date":493,"type":31},"2025-06-08",{"date":379,"type":21},{"date":496,"type":21},"2027-06-03",{"name":37,"class":38},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":506,"minAge":257,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":437},"100495980","frailty-assessments-for-risk-assessment-in-gynecologic-oncology-patients-100495980","NCT05738252","Frailty Assessments for Risk Assessment in Gynecologic Oncology Patients","Frailty Assessments for Risk Assessment in Gynecologic Oncology Patients Undergoing Surgery and Chemotherapy","FARGO","Inclusion Criteria:\n\n1. Age must be 55 years or older at registration\n2. Must meet any one of the following criteria:\n\n   1. Have stage II-IV ovarian or endometrial cancer, undergoing cytoreductive surgery via laparotomy, with or without neoadjuvant chemotherapy (NACT)\n   2. Have any stage endometrial, uterine or cervical cancer planned for laparotomy where laparoscopy is deemed unfeasible\u002Fhigh-risk due to comorbidities\n   3. Are undergoing laparotomy for pelvic mass, highly suspicious for malignancy; or\n   4. Are undergoing laparotomy for gynecologic malignancy recurrence.\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\n2. Require urgent surgery within 24 hours of first consultation to the Gynecological Oncology team\n3. Are undergoing neoadjuvant radiation therapy\n4. Have a previously documented history of dementia\n5. Have cognitive, language, vision, or hearing impairment that impacts ability to understand the directions for the completion of the study instruments\n6. Are participating in a clinical trial investigating a new systemic therapy","FEMALE","110 Years",{"count":509,"type":21},280,"FARGO is a prospective cohort study that aims to determine the performance of preoperative frailty assessment based on the Frailty Phenotype (FP), compared to a perioperative cardiovascular risk assessment based on the combination of preoperative Revised Cardiac Risk Index (RCRI), age and occurrence of myocardial injury after noncardiac surgery (MINS), in predicting the composite of all-cause death or new disability at 6 months after surgery in patients aged 55 or older. Patients will have confirmed or suspected gynecologic cancer, undergoing cytoreductive or high-risk surgery with or without chemotherapy.",[512,513,514],"Gynecologic Cancer","Frailty","Oncology","2025-04-12",{"date":517,"type":31},"2025-04-16",{"date":519,"type":31},"2023-06-15",{"date":521,"type":21},"2025-10",{"name":37,"class":38},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":50,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":545},"100414732","phase-2-safety-of-continuing-her-2-directed-therapy-in-overt-left-ventricular-dysfunction-100414732","NCT04680442","Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction: A Randomized, Controlled Trial","SCHOLAR-2","Inclusion Criteria:\n\n1. Stage I-III HER-2 positive breast cancer\n2. Receiving adjuvant or neoadjuvant therapy with trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1)\n3. Evidence of left ventricular dysfunction, as defined by at least one of:\n\n   a) LVEF \\\u003C 54% or b) LVEF ≥54% and either i) fall in LVEF of ≥15% from prior to trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) exposure, or ii) New York Heart Association (NYHA) class II heart failure symptoms within the past 6 months\n\nExclusion Criteria:\n\n1. Current use of both angiotensin converting enzyme inhibitor (ACEI) \u002Fangiotensin receptor blocker (ARB) and beta-blocker\n2. Contra-indication to both ACE-I\u002FARB and beta-blockers\n3. NYHA class III or IV heart failure\n4. LVEF \\\u003C40%\n5. Systolic blood pressure \\\u003C100mmHg\n6. Current or planned pregnancy or breastfeeding",{"count":532,"type":21},130,[128],"Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned. Heart injury can often be successfully treated using cardiac medications. The objectives of SCHOLAR-2 are to evaluate whether is it safe and effective to continue trastuzumab, pertuzumab or trastuzumab-emtansine (T-DM1) in patients with early stage HER-2 positive breast cancer despite mild, minimally symptomatic or asymptomatic systolic left ventricular dysfunction as compared with a guideline-driven approach of withholding or discontinuing trastuzumab, pertuzumab or trastuzumab-emtansine (T-DM1).\n\nIn SCHOLAR-2, we will compare two thresholds of withholding or discontinuing trastuzumab\u002Fpertuzumab\u002Ftrastuzumab-emtansine: a threshold that is currently advocated for by existing treatment practice guidelines versus a more aggressive threshold that allows trastuzumab\u002Fpertuzumab\u002Ftrastuzumab-emtansine to continue at lower levels of LVEF than currently supported by guideline documents.",[536,537],"Breast Cancer","Heart Failure","2025-04-03",{"date":540,"type":31},"2025-04-06",{"date":542,"type":31},"2021-07-01",{"date":144,"type":21},{"name":37,"class":38},8,{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":554,"sex":18,"minAge":555,"maxAge":507,"enrollmentInfo":556,"targetDuration":4,"studyType":50,"phases":558,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":437},"100533775","the-effect-of-retrograde-autologous-priming-on-transfusion-requirements-after-cardiac-surgery-100533775","NCT06230198","The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery","The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery (TheRAPy): a Multiple Period Vanguard Cluster Crossover Trial","TheRAPy","Inclusion Criteria:\n\n* Hospitals completing \\>200 adult cardiac surgical cases a year; (ii) 95% of cardiovascular surgery group (i.e., cardiac anesthesiologists, surgeons, and perfusionists) agree to manage patients under both autologous priming policies as per their randomization schedule for the duration of the trial.\n* All patients undergoing cardiac surgery on cardiopulmonary bypass at an enrolled site during the trial period will be included in data collection.\n\nExclusion Criteria:\n\n* Complete \\\u003C=200 cardiac surgical cases.\n* \\\u003C95% of their cardiovascular surgery group agrees to manage patients according to either of the two policies.",true,"10 Years",{"count":557,"type":21},4500,[52],"The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.",[561],"Red Blood Cell Transfusion","2025-02-27",{"date":564,"type":31},"2025-03-04",{"date":566,"type":31},"2024-12-04",{"date":568,"type":21},"2026-11",{"name":37,"class":38},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":50,"phases":579,"briefSummary":580,"conditions":581,"keywords":582,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":588,"locationsCount":89},"100472664","surgical-ablation-of-af-efficacy-trial-100472664","NCT05434819","Surgical Ablation of AF Efficacy Trial","SAFE","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated cardiac surgical procedure: CABG, AVR, ascending aorta replacement, or combinations thereof;\n* Documented history of paroxysmal or persistent AF\n* Provide informed consent\n\nExclusion Criteria:\n\n* Dominant atrial arrhythmia is atrial flutter;\n* Documented left atrial diameter ≥ 6 cm;\n* Previous cardiac surgery requiring opening of the pericardium;\n* Patients undergoing any of the following procedures:\n\n  1. Heart transplant\n  2. Complex congenital heart surgery\n  3. Sole indication for surgery is ventricular assist device insertion\n  4. Mitral valve repair or replacement\n  5. Tricuspid valve repair or replacement\n* Patient resides in a long-term care facility",{"count":578,"type":21},2000,[52],"SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.",[264,537],[583,426],"Surgical Ablation",{"date":564,"type":31},{"date":586,"type":31},"2023-06-01",{"date":307,"type":21},{"name":37,"class":38},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":50,"phases":599,"briefSummary":600,"conditions":601,"keywords":602,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":612,"locationsCount":613},"100494919","virtual-care-to-improve-outcomes-and-recovery-from-heart-failure-hospitalization-100494919","NCT05724433","VIrtual Care To Improve Outcomes and RecoverY From Heart Failure Hospitalization","VIrtual Care To Improve Outcomes and RecoverY From Heart Failure Hospitalization (VICTORY-HF) RCT","VICTORY-HF","Inclusion Criteria:\n\nAdult patients ≥ 18 years old who:\n\n1. Are being discharged after hospitalization or urgent visit for HF as\n\n   1. a primary diagnosis or\n   2. significant complication (prolonging length of stay) of another diagnosis OR Have been referred for an initial consult at a cardiology clinic within 1 week of hospitalization or urgent visit for HF as a primary or secondary diagnosis, as described above.\n2. Have left ventricular ejection fraction (LVEF) \\\u003C 50% within the preceding 3 months.\n3. Have NT-proBNP of \\> 900 pg\u002Fml during hospital admission or within 7 days after discharge from the ED\n4. Have a mailing address for patient or caregiver\n5. Provide verbal consent\n\nExclusion Criteria:\n\n1. Died or left hospital before medically advised hospital discharge\n2. Unable to self-assess or communicate symptoms (e.g. clinically evident dementia)\n3. Unable to engage with digital health technology or follow up\n4. Severe valve disease\n5. Recipient of or on waiting list for LVAD or cardiac transplant\n6. Complex congenital heart disease, hypertrophic obstructive cardiomyopathy, or amyloid cardiomyopathy\n7. Severe lung disease with symptoms on minimal exertion, forced expiratory volume during 1 second (FEV1) \\\u003C 1 litre, severe pulmonary hypertension with RVSP \\> 60 mm Hg, or on home oxygen\n8. Severe kidney disease (persistent eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2)\n9. Active malignancy\n10. Receiving palliative care or expected life expectancy \\\u003C 6 months",{"count":598,"type":21},891,[52],"The clinic visits (intervention) will continue for 90 days, which represents the follow-up period for the primary medication and health status outcomes. The co-primary clinical outcomes will be obtained at 180 days.",[537],[537,603,604,605],"Randomized Controlled Trial","Digital Health","Knowledge Translation","2024-12-27",{"date":608,"type":31},"2024-12-31",{"date":610,"type":31},"2023-01-23",{"date":307,"type":21},{"name":37,"class":38},9,{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":18,"minAge":186,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":50,"phases":622,"briefSummary":623,"conditions":624,"keywords":627,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":637,"locationsCount":116},"100429813","post-discharge-after-surgery-virtual-care-with-remote-automated-monitoring-technology-2-pvc-ram-2-trial-100429813","NCT04876950","Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-2 (PVC-RAM-2) Trial","PVC-RAM-2","Inclusion Criteria:\n\n1. are ≥40 years of age;\n2. will undergo or have undergone semi-urgent, urgent, or emergency surgery requiring expected hospital stay of ≥2 days; and\n3. provide informed consent to participate.\n\nExclusion Criteria:\n\n1. planned transfer to a rehabilitation or convalescent facility, or repatriation from trial hospital site to local community hospital following surgery;\n2. are unable to communicate with research staff, complete study surveys, or undertake an interview using a tablet computer due to a language barrier or a cognitive, visual, or hearing impairment; or\n3. reside in an area without cellular network coverage.",{"count":578,"type":21},[52],"The Post discharge after surgery Virtual Care with Remote Automated Monitoring technology-2 (PVC-RAM-2) Trial is a multicentre, parallel group, superiority, randomized controlled trial to determine the effect of virtual care with remote automated monitoring (RAM) technology compared to standard care on acute-hospital care during the 45-day follow up after randomization, in adults who have undergone semi-urgent (e.g., oncology), urgent (e.g., hip fracture), or emergency (e.g., ruptured abdominal aortic aneurysm) surgery. Secondary outcomes at 45 days after randomization include 1) days in hospital; 2) index length of hospital stay; 3) hospital re-admission; 4) emergency department visit; 5) medication error detection; 6) medication error correction; and 7) surgical site infection. Additional secondary outcomes are pain of any severity, and moderate-to-severe pain assessed at 15 and 45 days. We will also assess optimal management of long-term health by evaluating among self-reported current smokers and those with atherosclerotic disease, whether patients are taking classes of efficacious medications at 45 days post randomization.",[625,626],"Surgery","Perioperative Complication",[628,629,630],"Virtual care","Remote monitoring","Acute hospital care","2024-11-13",{"date":633,"type":31},"2024-11-15",{"date":635,"type":31},"2024-10-04",{"date":245,"type":21},{"name":37,"class":38},{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":646,"enrollmentInfo":647,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":649,"conditions":650,"keywords":651,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":659,"locationsCount":660},"100556027","detection-of-perioperative-atrial-fibrillation-after-noncardiac-surgery-100556027","NCT06519747","DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery","Enhanced DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery with Continuous Electrocardiographic Monitoring","DETECT-POAF","Inclusion Criteria:\n\n1. Had undergone noncardiac surgery within the past 72 hours and requiring, or expected to require, at least one of the following:\n\n   * an overnight hospital admission after surgery\n   * day surgery that would result in a large enough physiological insult to be able to cause POAF. Procedures excluded include those that are conducted using local anesthesia alone, are less than 30 minutes in duration, and\u002For are judged to be of low physiologic insult by the local investigator.\n2. Have one of the following high-risk criteria;\n\n   * age 55-64 years, and having either established cardiovascular disease, recent major vascular surgery, a CHA2DS2-VASc score ≥3, or an elevated postoperative troponin level;\n   * age 65-74 years, and having either established cardiovascular disease, recent major vascular surgery, a CHA2DS2-VASc score ≥2, or an elevated postoperative troponin level; or\n   * age ≥75 years;\n3. Provide written informed consent to participate.\n\nExclusion Criteria:\n\n1. History of documented chronic (i.e., non-transient) AF before noncardiac surgery;\n2. Need for long-term systemic anticoagulation;\n3. Ongoing need for long-term dual antiplatelet treatment;\n4. Contraindication to oral anticoagulation;\n5. Severe renal insufficiency;\n6. Severe liver cirrhosis;\n7. Acute stroke in the past 14 days;\n8. Underwent cardiac surgery in the past 35 days;\n9. History of nontraumatic intracranial, intraocular, or spinal bleeding;\n10. Hemorrhagic disorder or bleeding diathesis;\n11. Known life expectancy \\\u003C1 year due to concomitant disease;\n12. Women who are pregnant, breastfeeding, or of childbearing potential not taking effective contraception;\n13. Expected to be non-compliant with follow-up and\u002For device use;\n14. Known contact allergy to monitoring device and\u002For its peripheral components;\n15. Previously enrolled in DETECT-POAF.","120 Years",{"count":648,"type":21},750,"This is a multicentre prospective cohort study where patients will receive up to 14 days of continuous ECG monitoring by wearing a portable monitoring device, starting within 72 hours after noncardiac surgery.",[264,422],[652],"Cardiac monitoring","2024-11-05",{"date":655,"type":31},"2024-11-07",{"date":657,"type":31},"2024-10-15",{"date":307,"type":21},{"name":37,"class":38},6,""]